Manager × security

Aisling Capital Management LP BBIO holdings history

Who else holds this security?

BRIDGEBIO PHARMA INC · CUSIP 10806X102 · CIK 1766721

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Aisling Capital Management LP reported 4.59M BBIO (shares), valued at $341.83M, or 72.48% of its reported non-derivative portfolio. Filed 2026-08-13.

Verify history & sources
Portfolio weight and quantity history
Reported portfolio weight
72.48%
Shares
4.59M
4,589,611
Reported value
$341.83M
USD

Shares decreased 9.82%; reported value decreased 9.56%, and weight changed -6.87 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 202672.48%4,589,611SEC filingFiled Aug 13, 2026
Q1 202679.35%5,089,611SEC filingFiled May 5, 2026
Q4 202581.29%5,089,611SEC filingFiled Feb 10, 2026
Q3 202569.29%6,089,611SEC filingFiled Nov 12, 2025
Q2 202572.85%6,068,125SEC filingFiled Aug 13, 2025
Q1 202572.72%6,068,125SEC filingFiled May 13, 2025
Q4 202459.08%6,068,125SEC filingFiled Feb 12, 2025
Q3 202459.18%6,068,125SEC filingFiled Nov 13, 2024
Q2 202466.52%6,068,125SEC filingFiled Aug 8, 2024
Q1 202463.50%6,068,125SEC filingFiled May 14, 2024
Q4 202373.07%6,068,125SEC filingFiled Feb 7, 2024
Q3 202365.94%6,068,125SEC filingFiled Nov 13, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 202365.94%6,068,125$160.02MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing
Filed Nov 13, 2023
Q4 202373.07%6,068,125$244.97MShares unchanged; reported value increased 53.09%, and weight changed +7.13 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Feb 7, 2024
Q1 202463.50%6,068,125$187.63MShares unchanged; reported value decreased 23.41%, and weight changed -9.57 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed May 14, 2024
Q2 202466.52%6,068,125$153.71MShares unchanged; reported value decreased 18.08%, and weight changed +3.02 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Aug 8, 2024
Q3 202459.18%6,068,125$154.49MShares unchanged; reported value increased 0.51%, and weight changed -7.34 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Nov 13, 2024
Q4 202459.08%6,068,125$166.51MShares unchanged; reported value increased 7.78%, and weight changed -0.10 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Feb 12, 2025
Q1 202572.72%6,068,125$209.78MShares unchanged; reported value increased 25.98%, and weight changed +13.64 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed May 13, 2025
Q2 202572.85%6,068,125$262.02MShares unchanged; reported value increased 24.91%, and weight changed +0.13 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Aug 13, 2025
Q3 202569.29%6,089,611$316.29MShares increased 0.35%; reported value increased 20.71%, and weight changed -3.56 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Nov 12, 2025
Q4 202581.29%5,089,611$389.30MShares decreased 16.42%; reported value increased 23.08%, and weight changed +12.00 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Feb 10, 2026
Q1 202679.35%5,089,611$377.95MShares unchanged; reported value decreased 2.92%, and weight changed -1.94 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed May 5, 2026
Q2 202672.48%4,589,611$341.83MShares decreased 9.82%; reported value decreased 9.56%, and weight changed -6.87 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Aug 13, 2026
Aisling Capital Management LP · BRIDGEBIO PHARMA INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1766721","quarter":"2026Q2","cusip":"10806X102"}

get_institutional_manager_history
{"cik":"1766721","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.